Clinical trials: Cancer of Endometrium Stage II
Breast Cancer, Endometrial Cancer
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
RATIONALE: BI 2536 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well BI 2536 works in treating patients with…
- Conditions
- Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Melanoma (Skin)
- Trial name
- NCT00526149
- Testing
- BI 2536, high performance liquid chromatography, mass spectrometry
- Where
- Belgium
- Volunteers
- 76 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Metastatic Cancer, Endometrium Cancer
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
It's propose this pilot phase 2 study to explore the combination therapy of futibatinib with pembrolizumab in patients with metastatic microsatellite stable (MSS) endometrial carcinoma to provide a well-tolerated regimen for…
- Conditions
- Metastatic Cancer, Endometrium Cancer, Endometrial Carcinoma
- Trial name
- NCT05036681
- Testing
- Futibatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- M.D. Anderson Cancer Center
Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer
Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer
This research study is studying racial and genetic biomarkers of response in tissue samples from patients with endometrial cancer.
- Conditions
- Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer
- Trial name
- NCT01198171
- Testing
- Laboratory Biomarker Analysis, Study of Socioeconomic and Demographic Variables
- Where
- United States
- Volunteers
- 243 people
- Sponsor
- Gynecologic Oncology Group
Endometrial Stromal Sarcoma, Adenosarcoma of Uterus
FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study
This phase 2 clinical trial aims to evaluate the efficacy of Fulvestrant, an ER-antagonist, in women with estrogen receptor positive (ER+) low-grade gynecological cancers.
- Conditions
- Endometrial Stromal Sarcoma, Adenosarcoma of Uterus, Leiomyosarcoma Uterus, Endometrial Cancer
- Trial name
- FUCHSia (NCT03926936)
- Testing
- Fulvestrant
- Where
- 14 sites in Belgium, Netherlands
- Volunteers
- 17 people
- Sponsor
- Frederic Amant
Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma
Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer
This phase II trial tests how well elacestrant with everolimus works for the treatment of estrogen receptor (ER) positive endometrial cancer that has come back after a period of improvement (recurrent), that may have spread from…
- Conditions
- Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Stage III Endometrial Cancer
- Trial name
- NCT07634601
- Testing
- Biospecimen Collection, Computed Tomography, Elacestrant
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Endometrial Cancer
Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- PORTEC-3 (NCT00411138)
- Testing
- Radiation Therapy, cisplatin, carboplatin
- Where
- Netherlands
- Volunteers
- 670 people
- Sponsor
- Leiden University
Endometrial Cancer
Everolimus in Treating Patients With Relapsed or Metastatic Endometrial Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- ENDORAD (NCT00870337)
- Testing
- everolimus
- Where
- France
- Volunteers
- 44 people
- Sponsor
- ARCAGY/ GINECO GROUP
Atypical Endometrial Hyperplasia, Stage I Uterine Corpus Cancer AJCC v7
Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer
This phase II trial studies how well levonorgestrel-releasing intrauterine system works in treating patients with complex atypical hyperplasia or grade I endometrial cancer.
- Conditions
- Atypical Endometrial Hyperplasia, Stage I Uterine Corpus Cancer AJCC v7, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7
- Trial name
- NCT00788671
- Testing
- Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System, Quality-of-Life Assessment
- Where
- 7 sites in United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Cancer
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005583
- Testing
- cisplatin, doxorubicin hydrochloride, epirubicin hydrochloride
- Where
- 23 sites in Belgium, France and 9 more
- Volunteers
- 400 people
- Sponsor
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Endometrial Adenocarcinoma, Recurrent Uterine Corpus Carcinoma
Prognostic Biomarkers in Patients With Endometrial Cancer
This research study is studying prognostic biomarkers in tissue samples from patients with endometrial cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that…
- Conditions
- Endometrial Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer
- Trial name
- NCT01208467
- Testing
- Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 2,824 people
- Sponsor
- Gynecologic Oncology Group
Cancer Survivor, Endometrial Carcinoma
Health and Recovery Program in Increasing Physical Activity Level in Stage IA-IIIA Endometrial Cancer Survivors
This randomized phase II trial studies how well a health and recovery program works in increasing physical activity level in stage IA-IIIA endometrial cancer survivors.
- Conditions
- Cancer Survivor, Endometrial Carcinoma, Stage I Uterine Corpus Cancer AJCC v7, Stage IA Uterine Corpus Cancer AJCC v7
- Trial name
- NCT03367923
- Testing
- Communication Intervention, Counseling, Fitbit tracker
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Stanford University
Lynch Syndrome, Recurrent Uterine Corpus Carcinoma
Biomarkers in Samples From Patients With Endometrial Cancer
This research study is studying biomarkers in samples from patients with endometrial cancer. Studying samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify…
- Conditions
- Lynch Syndrome, Recurrent Uterine Corpus Carcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer
- Trial name
- NCT01199250
- Testing
- Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- Gynecologic Oncology Group
Endometrial Carcinoma, Recurrent Uterine Corpus Carcinoma
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
This randomized phase II trial studies how well temsirolimus with or without megestrol acetate and tamoxifen citrate works in treating patients with endometrial cancer that has spread to other places in the body and usually…
- Conditions
- Endometrial Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer
- Trial name
- NCT00729586
- Testing
- Laboratory Biomarker Analysis, Megestrol Acetate, Tamoxifen Citrate
- Where
- 108 sites in United States
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Endometrial Adenocarcinoma, Stage III A, B, C
A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation
The purpose of this study is to determine the effectiveness of the combination of the two drugs, docetaxel (Taxotere®) and carboplatin (Paraplatin®) followed by radiation directed at the tumor in treating your endometrial cancer.
- Trial name
- NCT00285415
- Testing
- Docetaxel and Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Carilion Clinic
Endometrial Cancer Stage I, Endometrial Cancer Stage II
Cost-utility of Ambulatory Surgery in the Management of Endometrial Cancer(AMBU-ENDO)
To date, cost-utility, safety, and feasibility of ambulatory surgery versus traditional pathway in the management of endometrial cancer have never been prospectively assessed.
- Trial name
- AMBU-ENDO (NCT03580421)
- Testing
- ambulatory surgery, standard surgery
- Where
- 9 sites in France
- Volunteers
- 77 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cervical Cancer, Endometrial Cancer
Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer
- Trial name
- NCT00032162
- Testing
- carboplatin, pegylated liposomal doxorubicin hydrochloride
- Where
- 19 sites in Germany
- Volunteers
- 63 people
- Sponsor
- AGO Study Group
Endometrial Cancer
Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy, such as liposome-encapsulated doxorubicin citrate and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01100359
- Testing
- carboplatin, liposome-encapsulated doxorubicin citrate, laboratory biomarker analysis
- Where
- Austria
- Volunteers
- 39 people
- Sponsor
- Medical University Innsbruck
Endometrial Cancer
Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer
RATIONALE: Lymphadenectomy may remove cancer cells that have spread to nearby lymph nodes. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003749
- Testing
- adjuvant therapy, conventional surgery, brachytherapy
- Where
- 3 sites in United Kingdom
- Volunteers
- 2,300 people
- Sponsor
- Medical Research Council
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Colorectal Cancer, Endometrial Cancer
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 and/or sargramostim may be a more effective treatment for solid tumors.
- Conditions
- Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00019331
- Testing
- aldesleukin, ras peptide cancer vaccine, sargramostim
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)